These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 34227124)

  • 1. Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia.
    Quinn CT; Niss O; Dong M; Pfeiffer A; Korpik J; Reynaud M; Bonar H; Kalfa TA; Smart LR; Malik P; Ware RE; Vinks AA; McGann PT
    Br J Haematol; 2021 Aug; 194(3):617-625. PubMed ID: 34227124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia.
    McGann PT; Niss O; Dong M; Marahatta A; Howard TA; Mizuno T; Lane A; Kalfa TA; Malik P; Quinn CT; Ware RE; Vinks AA
    Am J Hematol; 2019 Aug; 94(8):871-879. PubMed ID: 31106898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.
    Dong M; McGann PT; Mizuno T; Ware RE; Vinks AA
    Br J Clin Pharmacol; 2016 Apr; 81(4):742-52. PubMed ID: 26615061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
    Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
    Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.
    Aygun B; Lane A; Smart LR; Santos B; Tshilolo L; Williams TN; Olupot-Olupot P; Stuber SE; Tomlinson G; Latham T; Ware RE;
    Lancet Haematol; 2024 Jun; 11(6):e425-e435. PubMed ID: 38701812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy.
    Estepp JH; Smeltzer MP; Kang G; Li C; Wang WC; Abrams C; Aygun B; Ware RE; Nottage K; Hankins JS
    Am J Hematol; 2017 Dec; 92(12):1333-1339. PubMed ID: 28913922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia.
    Flanagan JM; Steward S; Howard TA; Mortier NA; Kimble AC; Aygun B; Hankins JS; Neale GA; Ware RE
    Br J Haematol; 2012 Apr; 157(2):240-8. PubMed ID: 22360576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection from sickle cell retinopathy is associated with elevated HbF levels and hydroxycarbamide use in children.
    Estepp JH; Smeltzer MP; Wang WC; Hoehn ME; Hankins JS; Aygun B
    Br J Haematol; 2013 May; 161(3):402-5. PubMed ID: 23384083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia.
    Ware RE; Despotovic JM; Mortier NA; Flanagan JM; He J; Smeltzer MP; Kimble AC; Aygun B; Wu S; Howard T; Sparreboom A
    Blood; 2011 Nov; 118(18):4985-91. PubMed ID: 21876119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale, Development, and Validation of HdxSim, a Clinical Decision Support Tool for Model-Informed Precision Dosing of Hydroxyurea for Children with Sickle Cell Anemia.
    Power-Hays A; Dong M; Punt N; Mizuno T; Smart LR; Vinks AA; Ware RE
    Clin Pharmacol Ther; 2024 Sep; 116(3):670-677. PubMed ID: 38018175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure.
    Estepp JH; Wiczling P; Moen J; Kang G; Mack JM; Liem R; Panepinto JA; Garg U; Kearns G; Neville KA
    Br J Clin Pharmacol; 2018 Jul; 84(7):1478-1485. PubMed ID: 28884840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use.
    Green NS; Manwani D; Qureshi M; Ireland K; Sinha A; Smaldone AM
    Pediatr Blood Cancer; 2016 Dec; 63(12):2146-2153. PubMed ID: 27573582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroyxurea improves cerebral oxygen saturation in children with sickle cell anemia.
    Karkoska K; Quinn CT; Niss O; Pfeiffer A; Dong M; Vinks AA; McGann PT
    Am J Hematol; 2021 May; 96(5):538-544. PubMed ID: 33534136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opportunities for model-based precision dosing in the treatment of sickle cell anemia.
    Dong M; Mizuno T; Vinks AA
    Blood Cells Mol Dis; 2017 Sep; 67():143-147. PubMed ID: 28807656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings.
    Inusa BPD; Wale A; Hassan AA; Idhate T; Dogara L; Ijei I; Qin Y; Anie K; Lawson JO; Hsu L
    F1000Res; 2018; 7():. PubMed ID: 30228870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia.
    Walker AL; Steward S; Howard TA; Mortier N; Smeltzer M; Wang YD; Ware RE
    Blood; 2011 Nov; 118(20):5664-70. PubMed ID: 21921042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxyurea: Analytical techniques and quantitative analysis.
    Marahatta A; Ware RE
    Blood Cells Mol Dis; 2017 Sep; 67():135-142. PubMed ID: 28847416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.
    Ware RE; Davis BR; Schultz WH; Brown RC; Aygun B; Sarnaik S; Odame I; Fuh B; George A; Owen W; Luchtman-Jones L; Rogers ZR; Hilliard L; Gauger C; Piccone C; Lee MT; Kwiatkowski JL; Jackson S; Miller ST; Roberts C; Heeney MM; Kalfa TA; Nelson S; Imran H; Nottage K; Alvarez O; Rhodes M; Thompson AA; Rothman JA; Helton KJ; Roberts D; Coleman J; Bonner MJ; Kutlar A; Patel N; Wood J; Piller L; Wei P; Luden J; Mortier NA; Stuber SE; Luban NLC; Cohen AR; Pressel S; Adams RJ
    Lancet; 2016 Feb; 387(10019):661-670. PubMed ID: 26670617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxycarbamide: clinical aspects.
    Ware RE
    C R Biol; 2013 Mar; 336(3):177-82. PubMed ID: 23643402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.
    Zimmerman SA; Schultz WH; Davis JS; Pickens CV; Mortier NA; Howard TA; Ware RE
    Blood; 2004 Mar; 103(6):2039-45. PubMed ID: 14630791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.